Pharmaceutical

GSK concludes Aiolos Bio acquisition for $1.4bn

GSK has successfully concluded the acquisition of Aiolos Bio in a deal that could reach $1.4bn, expanding its respiratory portfolio.

Feb 16, 2024 - 18:00
GSK concludes Aiolos Bio acquisition for $1.4bn
GSK has successfully concluded the acquisition of Aiolos Bio in a deal that could reach $1.4bn, expanding its respiratory portfolio.
Read the original article

Tags:

Previous Article

Xyphos and Kelonia link for immuno-oncology drug development

Next Article

Psychedelic treatments for mental health: Is there substance behind the hype?

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Opinion: A new HHS rule takes a far too narrow approach to health care data interoperability

Opinion: A new HHS rule takes a far too narrow approach...

Jan 18, 2024

Excitement associated with FDA approval of Rinvoq in Crohn’s disease

Excitement associated with FDA approval of Rinvoq in Cr...

May 26, 2023

Eculizumab biosimilar by Turgut Ilaclari for Neuromyeli...

Jul 1, 2023